216 related articles for article (PubMed ID: 23053221)
1. Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis.
Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Arch Dermatol Res; 2013 Jan; 305(1):17-23. PubMed ID: 23053221
[TBL] [Abstract][Full Text] [Related]
2. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis.
Yanaba K; Hayashi M; Yoshihara Y; Nakagawa H
J Dermatol; 2016 Aug; 43(8):954-7. PubMed ID: 26945563
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.
Yanaba K; Asano Y; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2012 Sep; 22(5):668-75. PubMed ID: 22160844
[TBL] [Abstract][Full Text] [Related]
6. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease.
Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Shimizu K; Sato S
Int J Rheum Dis; 2013 Aug; 16(4):442-7. PubMed ID: 23992266
[TBL] [Abstract][Full Text] [Related]
7. Increased serum pentraxin 3 in patients with systemic sclerosis.
Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
[TBL] [Abstract][Full Text] [Related]
8. Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: a cohort study.
Almeida I; Oliveira Gomes A; Lima M; Silva I; Vasconcelos C
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):37-42. PubMed ID: 26885625
[TBL] [Abstract][Full Text] [Related]
9. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
10. Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C.
Wang D; Zhou D; Du Q; Liang Q; Wang Q; Fang L; Wang G; Fan Q; Liu B; Zhou J; Tang Z; Wu H; Guo X; Jiao Y; Zhang G
Mol Med Rep; 2013 Apr; 7(4):1197-202. PubMed ID: 23426717
[TBL] [Abstract][Full Text] [Related]
11. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
[TBL] [Abstract][Full Text] [Related]
12. Effect of soluble inducible costimulator level and its polymorphisms on age-related macular degeneration.
Yu H; Zou X; Peng L; Wang Y; Zhang C; Chen B; Zou Y
DNA Cell Biol; 2013 Dec; 32(12):717-21. PubMed ID: 24083358
[TBL] [Abstract][Full Text] [Related]
13. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.
Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2012 Aug; 22(4):576-83. PubMed ID: 22075605
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
[TBL] [Abstract][Full Text] [Related]
17. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis.
Yanaba K; Asano Y; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2012 Sep; 167(3):542-7. PubMed ID: 22540233
[TBL] [Abstract][Full Text] [Related]
18. Aberrant production of soluble inducible T cell co‑stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B.
Wang D; Du Q; Luo G; Wang Q; Wang G; Zhang G; Leng Z; Guo X
Mol Med Rep; 2017 Dec; 16(6):8556-8562. PubMed ID: 28983583
[TBL] [Abstract][Full Text] [Related]
19. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.
Kuzumi A; Yoshizaki A; Toyama S; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Asano Y; Sato S
J Dermatol; 2018 Oct; 45(10):1216-1220. PubMed ID: 30004593
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage.
Ogawa F; Shimizu K; Hara T; Muroi E; Hasegawa M; Takehara K; Sato S
Clin Exp Rheumatol; 2008; 26(4):659-62. PubMed ID: 18799101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
